Latest twist in uniQure’s tale: possible sale

Five years after returning to the public markets, uniQure may be on the block.

While the Dutch gene therapy play declined to comment on a Bloomberg report citing undisclosed sources that the biotech was exploring options, including a sale or partnerships, investors bid up shares of the rare disease play 12% to finish at its highest-ever close, $81.14, and a market cap of about $3.1 billion...